Pulmonary fibrosis in the aftermath of the Covid-19 era (Review)

The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical o...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2020-09, Vol.20 (3), p.2557-2560
Main Authors: Vasarmidi, Eirini, Tsitoura, Eliza, Spandidos, Demetrios A, Tzanakis, Nikolaos, Antoniou, Katerina M
Format: Article
Language:English
Subjects:
Adult respiratory distress syndrome
Biomarkers
Collagen
Coronaviruses
COVID-19
Cytokines
Development and progression
Fibroblasts
Health aspects
Inflammation
Lung diseases
Lymphocytes
Medical research
Middle East respiratory syndrome
Mortality
Nintedanib
Peptides
Pirfenidone
Pneumonia
Precision medicine
Prognosis
Pulmonary fibrosis
Review
Severe acute respiratory syndrome coronavirus 2
Studies
Ventilation
Ventilators
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2020.8980